Nadifloxacine-d5

Nadifloxacin-d5 (OPC7251-d5) is deuterium labeled Nadifloxacin. Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo[1][2][3][4][5].

OPC7251-d5

12352005

Antibiotic; Bacterial; DNA/RNA Synthesis; Interleukin Related; Isotope-Labeled Compounds

Anti-infection; Cell Cycle/DNA Damage; Immunology/Inflammation; Others

COVID-19-immunoregulation

Infection; Inflammation/Immunology

O=C(C1=CN2C(C)CCC3=C2C(C1=O)=CC(F)=C3N4CC([2H])([2H])C(O)([2H])C([2H])([2H])C4)O

C19H16D5FN2O4

365.41

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Jacobs, M.R. and P.C. Appelbaum, Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. Expert Opin Pharmacother, 2006. 7 (14) : p. 1957-66.|[3]Choudhury, S., et al., Efficacy and safety of topical nadifloxacin and benzoyl peroxide versus clindamycin and benzoyl peroxide in acne vulgaris: A randomized controlled trial. Indian J Pharmacol, 2011. 43 (6) : p. 628-31.|[4]Vogt K, et al. Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris. European Journal of Clinical Microbiology and Infectious Diseases, 1992, 11 (10) : 943-945. |[5]Kuwahara K, et al. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci. 2005 Apr;38 (1) :47-55.|[6]Yamakawa T, et al. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49 (3) :455-65.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-B0506S1/

Isotope-Labeled Compounds

No Development Reported

IL-1; IL-6; IL-8